What factors drove the changes in Elutia's revenue and profit?

What is the market's earnings forecast for Elutia next quarter?

What were the key takeaways from Elutia’s earnings call?

Did Elutia beat or miss consensus estimates last quarter?

What were the key takeaways from Elutia's earnings call?

What is the revenue and EPS growth rate for Elutia year over year?

What is Elutia's latest dividend and current dividend yield?

What does Elutia do and what are its main business segments?

- **Breakthrough Product Pipeline**: NXT-41x targeting 15%-20% post-surgical infection rates in breast reconstruction, with FDA submission for 41 base matrix in Q1 2026. 
- **Financial Resilience**: $44.4M cash post-BioEnvelope sale, enabling debt-free development and 16% YoY revenue growth to $3.3M. 
- **Strategic Focus**: Divesting SimpliDerm to concentrate resources on 41x, supported by 144 VAC engagements and KOL partnerships. 
- **Market Differentiation**: 66.8% gross margin validates cost leadership, while 41x's 30-day antibiotic elution addresses unmet need in high-risk mastectomy patients.

**【CEO Summary Section】**
- **Mission Focus**: Humanizing medicine by addressing postoperative infections in breast reconstruction, with a $1.5 billion market opportunity. 
- **Product Highlights**: 
  - EluPro (FDA-cleared drug-eluting bio-envelope) achieved $18M annualized run rate within 9 months, reducing infections via localized antibiotic delivery. 
  - NXT-41x (planned 2026 launch) combines biologic matrix with sustained-release antibiotics, targeting 15%-20% post-surgical infection rates. 
- **Strategic Moves**: 
  - SimpliDerm (acellular dermal matrix) divestiture to focus on high-growth 41x platform. 
  - New hires: Guido Neels (Board member) and Pete Ligotti (Chief Commercial Officer) to accelerate commercialization. 
- **Market Validation**: Studies show 62%-82% infection reduction with local antibiotic delivery, validating 41x's differentiated approach. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $3.3M (16% YoY growth), driven by direct distribution of Cardiovascular and SimpliDerm products. 
  - Gross Margin: 66.8% (up 12pts YoY), reflecting cost efficiencies from debt repayment and BioEnvelope sale. 
  - Adjusted EBITDA: -$4.2M (narrowed $0.8M YoY). 
- **Balance Sheet Strength**: 
  - $44.4M cash post-BioEnvelope sale to Boston Scientific ($88M), enabling debt repayment and 41x development. 
  - Class B shares converted to Class A, resolving NASDAQ compliance issues. 
- **Liquidity**: $8M in escrow for future milestones, supporting 2026 launch. 

**【Q&A Key Highlights】**
- **FDA Strategy**: 
  - NXT-41 submission prioritizes biocompatibility; 41x resubmission expected within months of 41 clearance. 
  - Targeting 2026H1 41x launch with 30-day antibiotic elution to cover post-drain removal risks. 
- **Commercial Readiness**: 
  - 144 VAC engagements for EluPro provide template for 41x reimbursement strategy. 
  - KOL partnerships with top plastic surgeons validate 41x's clinical need. 
- **Competitive Positioning**: 
  - 41x's uniform antibiotic distribution and 30-day elution surpasses 60%-80% reduction seen in plaster-based alternatives. 
  - Focus on high-risk mastectomy patients (15%-20% infection rate) vs. broader breast augmentation market.

Elutia Inc.(ELUT)-20260312-2025 Q4 Earnings call transcript

- **$88M Bio-Envelope Sale**: Transformed balance sheet, providing $49M cash runway for NXT 41X development.
- **NXT 41X Innovation**: Local antibiotic delivery addresses 15%-20% post-reconstruction infection rates, targeting Q1 2027 FDA approval.
- **Revenue Recovery**: SimpliDerm (+18% QoQ) and cardiovascular (+28% QoQ) drive $3.3M Q3 revenue, with >80% gross margins.
- **Litigation Resolution**: 94% of legacy lawsuits closed, final $0.7M liability resolved.

**【CEO Summary Section】**
- Elutia’s mission is to humanize medicine, focusing on breast reconstruction with NXT 41X, a next-gen antibiotic-eluting matrix targeting the $1.5B market with 15%-20% post-operative infection rates.
- NXT 41X uses local antibiotic delivery (rifampin and minocycline) for >30-day release, addressing the anatomical challenge of hypoperfusion in mastectomy sites.
- Strategic milestones: FDA approval of NXT 41 (Q2 2026), followed by 41X (Q1 2027), with SimpliDerm as the commercial foundation.
- Manufacturing at a state-of-the-art GMP facility in Maryland, ensuring low COGS and scalability.

**【CFO Financial Commentary】**
- Sold bio-envelope business (Eliupro, Kangaroo) to Boston Scientific for $88M, closing Q4 2025 with $49M net cash post-debt repayment.
- Q3 2025 continuing ops revenue: $3.3M (SimpliDerm: $2.4M, cardiovascular: $0.9M), up 18% and 28% QoQ, respectively.
- GAAP gross margin 55.8%, adj. EBITDA loss $2.7M, with SimpliDerm and cardiovascular driving high margins (>80%).
- Resolved 104/110 legacy lawsuits, remaining $0.7M liability.

**【Q&A Key Highlights】**
- **Eliupro Learnings**: Team expertise, FDA engagement, and commercial infrastructure (e.g., VAC packages) critical for 41X launch.
- **Manufacturing Transition**: NXT 41/41X produced in separate GMP facility, with 2026 process validation on track.
- **Cardiovascular Growth**: Direct sales rebound to $0.9M/Q3, targeting steady expansion with minimal upfront investment.
- **Clinical Evidence Plan**: Preclinical data (e.g., 4-week efficacy) and post-launch clinical studies to drive full market adoption.

Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript

- **EluPro Dominance**: 68% of BioEnvelope revenue, 49% Q/Q growth, 130% higher utilization per account.
- **NXT-41X Pipeline**: Base matrix FDA approval Q4 2026, antibiotic version Q1 2027, targeting 1 in 3 post-reconstruction complication rate.
- **Litigation Resolution**: 97/110 cases settled, removing strategic overhang.
- **Gross Margin Expansion**: 62.4% (up 4.2% YoY), driven by scale and high-margin cardiovascular products.
- **Strategic Deals Imminent**: Expect business development updates in weeks/months.

**【CEO Summary Section】**
- **EluPro Growth**: 49% sequential revenue growth, with 161 hospitals actively ordering. EluPro now accounts for 68% of BioEnvelope revenue, driven by 130% higher utilization compared to CanGaroo. Boston Scientific partners in 30% of cases.
- **Breast Reconstruction Pipeline**: NXT-41X, a drug-eluting biologic matrix, targets 1 in 3 women suffering complications post-reconstruction. Base matrix expected FDA approval by Q4 2026, antibiotic version in Q1 2027. 97% of VAC submissions approved, with 90 in progress.
- **Strategic Opportunities**: Multiple business development deals in final stages, aiming to enhance cash position and operational efficiency.

**【CFO Financial Commentary】**
- **Litigation Resolution**: 97 of 110 lawsuits settled, reducing future expenses and strategic distractions.
- **Revenue Performance**: Q2 BioEnvelope revenue $3.5M (vs. $2.6M YoY), cardiovascular patch sales $0.7M (double prior quarter). Adjusted EBITDA loss $3.8M, driven by R&D and pipeline investments.
- **Gross Margin Improvement**: 62.4% (up 4.2% YoY), benefiting from scale in BioEnvelope and high-margin cardiovascular products.
- **Cash Position**: $8.5M, with strategic transactions expected to bolster liquidity.

**【Q&A Highlights】**
- **EluPro Bottlenecks**: Production and inventory management optimized; growth tied to VAC approvals, with 12-15 new hospitals/month.
- **NXT-41X Regulatory Path**: Base matrix approved via 510(k), antibiotic version via PMA, leveraging EluPro's proven regulatory pathway.
- **Business Development Timeline**: Expect updates in weeks/months, focusing on value-enhancing transactions.

Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: BioEnvelope division up 31% YoY to $3.1 million, with EluPro driving 52% of BioEnvelope revenue.
- **Strategic Partnership**: Boston Scientific reps are actively selling EluPro in 125 institutions, with 10-12 new VACs added monthly.
- **Gross Margin Expansion**: In-sourcing antibiotic disc manufacturing could push EluPro gross margin to mid-70%.
- **Cash Efficiency**: Operating expenses down $1 million YoY, with Ligand royalty deferrals reducing cash burn.
- **Production Scale-Up**: New Gaithersburg facility will enable $140 million annual revenue potential.

**【CEO Summary Section】**
- **EluPro Revenue Growth**: BioEnvelope division revenue reached $3.1 million, up 31% year-over-year, driven by EluPro adoption. EluPro now constitutes 52% of BioEnvelope revenue, up from 32% in Q4 2024.
- **Boston Scientific Partnership**: 900 Boston Scientific reps are actively selling EluPro, with 125 institutions through Value Analysis Committees (VACs) and 130 VACs in process. This partnership aims to leverage Boston Scientific's salesforce to accelerate EluPro adoption.
- **Production Expansion**: New Gaithersburg, MD facility will in-source antibiotic disc manufacturing, reducing costs and increasing gross margin potential to mid-70%.
- **Cardiovascular Re-acquisition**: Direct sales of cardiovascular products from LeMaitre Vascular generated $600,000 in Q1, with 26 independent sales reps covering 100% of the top-line. Gross margin expected to reach 80%.

**【CFO Financial Commentary】**
- **Top-line Performance**: Total revenue $6.0 million (down 10% YoY but +10% sequentially). Adjusted EBITDA $3.3 million (vs. $4.5 million YoY).
- **Gross Margin**: 54.8% (flat YoY), with improvement expected from EluPro production scale-up and Cardiovascular direct sales.
- **Cost Control**: Operating expenses decreased $1 million YoY. Cash conservation initiatives (e.g., Ligand Pharmaceuticals royalty deferral, SWK Holdings term loan amendment) reduced cash burn by $2.2 million.
- **Liquidity**: $17.4 million cash on hand, with $13.7 million net proceeds from February registered direct offering.

**【Q&A Highlights】**
- **Boston Scientific Adoption**: EluPro adoption spreads organically within practices, with 10-12 VACs added monthly. Reps prioritize Boston Scientific pacemaker cases but expand usage to competitive devices.
- **Manufacturing Capacity**: Current EluPro capacity $25-30 million (without Gaithersburg expansion). Full production with Gaithersburg could support $140 million revenue.
- **Cash Burn**: Q2 cash flow ~$8 million (litigation settlement), stabilizing to $4-5 million post-Q2. Ligand royalty payments deferred to stock, reducing cash outflows.
- **Clinical Data**: Real-world registry study enrollment underway, with peer-reviewed publications validating EluPro's antibacterial efficacy.

Elutia (ELUT)-8 May 25-2025 Q1 Earnings call transcript

- **EluPro Breakthrough**: 18% Q4 growth, 65% repeat order boost, targeting $200M TYRX replacement market. 
- **Financial Strength**: 58% non-GAAP margin, $15M capital raise post-Q4. 
- **Strategic Wins**: Boston Scientific partnership, 100+ active accounts, 43 legacy lawsuits resolved. 
- **2025 Growth Drivers**: EluPro neurostimulator expansion, SimpliDerm recovery, zero-deficit FDA manufacturing.

**【CEO Summary Section】**
- **EluPro Market Dominance**: Achieved 18% Q4 growth in BioEnvelope sales, with EluPro accounting for 30% of revenue. Physicians reported 65% increase in repeat orders post-adoption. 
- **Operational Excellence**: FDA-cleared manufacturing facility scaled to $140M annual capacity, targeting >70% gross margin. 
- **Partnership Expansion**: Initiated rollout with Boston Scientific’s 900 reps to penetrate 1,400 high-volume cardiac centers. 
- **Competitive Advantage**: Biologic envelope reduces friction vs. Medtronic’s synthetic TYRX, capturing $85M annual “crossover” market. 

**【CFO Financial Commentary】**
- **Topline Growth**: Q4 revenue $5.5M (-7% YoY), driven by BioEnvelope ($2.7M +18% YoY). Full year revenue $24.4M (-1% YoY). 
- **Margin Expansion**: GAAP gross margin 43% (vs. 36% Q4 2023), non-GAAP 58% (vs. 51%). SimpliDerm line +12% YoY to $11.6M. 
- **Cash Management**: Settled $4.5M in legacy litigation, ending Q4 with $13.2M cash. Raised $15M via registered offering post-quarter. 

**【Q&A Highlights】**
- **Boston Scientific Rollout**: 900 reps to drive EluPro adoption, with commission-based incentives for avoiding Medtronic devices. 
- **SimpliDerm Recovery**: 12% YoY growth despite Sientra bankruptcy; partnership with Tiger Aesthetics stabilizing distribution. 
- **Litigation Resolution**: Reduced 79 pending cases to 43, saving $4.5M in Q4. Expect further reductions in 2025. 

**【Upcoming Catalysts】**
- HRS 2025 booth to showcase EluPro pediatric use case. Q1 2025 to report expanded GPO coverage and Boston Scientific integration metrics.

Actual	-15.79	-0.57	-0.5	-0.23	-0.81	-0.82	-0.6	-0.69	-0.73	-0.38	-0.49	-0.65	-0.5	-0.66	-0.75	-1.14	-0.33	-0.26	-0.21	-0.26	-0.19	1.48
Forecast	-0.52	-0.5025	-0.5525	-0.5325	-0.6225	-0.6825	-0.6233	-0.5575	-0.665	-0.69	-0.54	-0.29	-0.545	-0.285	-0.415	-0.33	-0.44	-0.25	-0.205	-0.17	-0.155	-0.14
Surprise	-2936.54%	-13.43%	+9.50%	+56.81%	-30.12%	-20.15%	+3.74%	-23.77%	-9.77%	+44.93%	+9.26%	-124.14%	+8.26%	-131.58%	-80.72%	-245.45%	+25.00%	-4.00%	-2.44%	-52.94%	-22.58%	+1157.14%

ELUT

ELUT fundamentals

ELUT Q4 2025 Earnings

Earnings Call

You can ask Aime

ELUT

ELUT fundamentals

ELUT Q4 2025 Earnings

Earnings Call

ELUT Earnings Call Summary for Q4/20255:00 PM on Mar 11, 2026

ELUT Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

ELUT Earnings Call Summary for Q2/20255:00 PM on Aug 14, 2025

ELUT Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

ELUT Earnings Call Summary for Q4/20244:30 PM on Mar 6, 2025

You can ask Aime